STOCK TITAN

Royalty Pharma plc (RPRX) Stock News, Jan-May 2024

RPRX NASDAQ

Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.

Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) reported 14% growth in Royalty Receipts driving Portfolio Receipts of $717 million for the first quarter of 2024. Full year 2024 guidance confirmed at $2,600 to $2,700 million with a commitment to grow dividends annually. The company's development-stage portfolio has expanded significantly, with key events expected in the coming year. Financial capacity of over $3.5 billion to execute transactions, despite a decline in Portfolio Receipts due to a high base of comparison. Strong Royalty Receipts growth and a focus on new royalty opportunities demonstrate a robust business strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) announced the acquisition of royalties and milestones on frexalimab from ImmuNext, Inc. for approximately $525 million. Frexalimab, developed by Sanofi, is a promising therapy for multiple sclerosis with blockbuster potential in various immune-mediated diseases. This acquisition expands Royalty Pharma's development-stage portfolio to 15 therapies, estimating to generate over $1 billion in peak royalties annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) received a $50 million milestone payment from Royalty Pharma plc for completing enrollment in the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen. Arrowhead stands to earn up to an additional $375 million from Amgen and $110 million from Royalty Pharma in milestone payments related to olpasiran. The rapid enrollment in the trial reflects the interest in olpasiran, developed using Arrowhead's TRiMTM technology. With three Phase 3 programs in progress, including plozasiran, Arrowhead continues to advance RNA interference therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
dividends earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
dividends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none

FAQ

What is the current stock price of Royalty Pharma (RPRX)?

Royalty Pharma (RPRX) last closed at $68.45.

What is the market cap of Royalty Pharma (RPRX)?

The market cap of Royalty Pharma (RPRX) is approximately $39.3B.